<div id="readability-page-1"><p>Shares of Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) were down 4.3% on Tuesday . The company traded as low as $55.92 and last traded at $56.01. Approximately 652,498 shares changed hands during trading, a decline of 65% from the average daily volume of 1,890,406 shares. The stock had previously closed at $58.51.</p><div><p><span></span><span>Get <strong>Exact Sciences</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><ul><li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li></ul><p>Several analysts recently weighed in on the stock. Benchmark  reaffirmed a &#34;buy&#34; rating and issued a $65.00 target price on shares of Exact Sciences in a report on Monday. Craig Hallum dropped their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, November 6th. BTIG Research lifted their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, November 26th. TD Cowen increased their target price on Exact Sciences from $82.00 to $86.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 26th. Finally, Bank of America cut their price target on Exact Sciences from $75.00 to $72.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, December 13th. One equities research analyst  has rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, Exact Sciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $72.94.</p><p><b>Get Our Latest Stock Report on Exact Sciences</b></p><h2>Exact Sciences Stock Performance</h2><ul><li>3 Hot Stocks Bought by Members of Congress: Follow the Money</li></ul><p>The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The company has a market cap of $9.34 billion, a price-to-earnings ratio of -43.11 and a beta of 1.24. The firm has a 50-day simple moving average of $57.20 and a 200 day simple moving average of $59.03. </p><p>Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The business had revenue of $708.66 million during the quarter, compared to analysts' expectations of $716.80 million. The company's revenue for the quarter was up 12.8% on a year-over-year basis.  On average, sell-side analysts predict that  Exact Sciences Co. will post -1.1 earnings per share for the current fiscal year. </p><h2>Insider Transactions at Exact Sciences</h2><ul><li>Time to buy these 3 healthcare companies that raised revenue guidance?</li></ul><p>In related news, CEO Kevin T. Conroy acquired 19,500 shares of Exact Sciences stock in a transaction on Wednesday, November 13th. The stock was purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders own  1.36% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently modified their holdings of the stock. Groupama Asset Managment acquired a new stake in shares of  Exact Sciences during the third quarter worth $821,000.  Sculptor Capital LP purchased a new position in  Exact Sciences during the 2nd quarter worth $32,819,000.  Samlyn Capital LLC acquired a new stake in shares of  Exact Sciences in the 2nd quarter worth $30,426,000.  Armistice Capital LLC boosted its holdings in shares of  Exact Sciences by 91.6% in the second quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company's stock valued at $59,154,000 after acquiring an additional 669,438 shares in the last quarter.  Finally, ArrowMark Colorado Holdings LLC acquired a new position in shares of  Exact Sciences during the third quarter worth about $28,608,000. Institutional investors and hedge funds own  88.82% of the company's stock. </p><h2>Exact Sciences Company Profile</h2> (Get Free Report)<p>Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.</p><h2>See Also</h2><ul><li>Five stocks we like better than Exact Sciences</li><li>Canada Bond Market Holiday: How to Invest and Trade </li><li>Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?</li><li>Best Stocks Under $10.00 </li><li>UnitedHealth Group Pulls Back Into Another Healthy Opportunity</li><li>How to invest in marijuana stocks in 7 steps </li><li>Micron Technology: Riding the AI Wave to Long-Term Growth</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Exact Sciences Right Now?</h2><p>Before you consider Exact Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.</p><p>While Exact Sciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EXAS

<p>Exact Sciences (NASDAQ:EXAS) shares fell 4.3% to $56.01, with trading volume down 65% from average levels. Analysts maintain a generally positive outlook, with a consensus rating of "Moderate Buy" and an average target price of $72.94. Recent quarterly earnings showed a revenue of $708.66 million, missing expectations. CEO Kevin T. Conroy purchased 19,500 shares, increasing his ownership. Institutional investors hold 88.82% of the stock, indicating strong institutional interest in the company, which specializes in cancer screening and diagnostic tests.</p>

Exact Sciences (NASDAQ:EXAS) Stock Price Down 4.3% - What's Next?